KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Taxes: 2010-2019

Historic Current Taxes for Biomarin Pharmaceutical (BMRN) over the last 8 years, with Mar 2019 value amounting to $11.4 million.

  • Biomarin Pharmaceutical's Current Taxes rose 11.06% to $11.4 million in Q1 2019 from the same period last year, while for Mar 2019 it was $11.4 million, marking a year-over-year increase of 11.06%. This contributed to the annual value of $7.8 million for FY2018, which is 20.07% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Current Taxes of $11.4 million as of Q1 2019, which was up 45.81% from $7.8 million recorded in Q4 2018.
  • Over the past 5 years, Biomarin Pharmaceutical's Current Taxes peaked at $59.6 million during Q4 2015, and registered a low of $5.7 million during Q1 2015.
  • Moreover, its 3-year median value for Current Taxes was $9.2 million (2018), whereas its average is $9.4 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Current Taxes surged by 987.28% in 2015 and then plummeted by 86.83% in 2016.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Current Taxes stood at $59.6 million in 2015, then plummeted by 86.83% to $7.8 million in 2016, then rose by 24.11% to $9.7 million in 2017, then declined by 20.07% to $7.8 million in 2018, then rose by 11.06% to $11.4 million in 2019.
  • Its last three reported values are $11.4 million in Q1 2019, $7.8 million for Q4 2018, and $8.6 million during Q3 2018.